A New Frontier in ALS: Prosetin's Promising Early Trial Results

NEW YORK, NY – June 16, 2026 – In the relentless battle against amyotrophic lateral sclerosis (ALS), a disease defined by its rapid progression and lack of effective treatments, every step forward is significant. Today, biotechnology company ProJenX announced a crucial milestone, revealing that its experimental drug, prosetin, has successfully cleared key safety and activity hurdles in an early-stage human trial. The interim data from the Phase 1b study offers a much-needed glimmer of hope, suggesting a new therapeutic avenue may be opening for this devastating neurodegenerative disease.

ProJenX reported that prosetin, a first-in-class, brain-penetrant MAP4K inhibitor, was found to be generally safe and well-tolerated by participants with ALS. More importantly, the drug demonstrated statistically significant target engagement, meaning it appears to be working at the molecular level precisely as intended. These findings, from the fully enrolled PRO-101 study involving 41 participants, provide a strong foundation for advancing prosetin into later-stage clinical development, a critical step in the long journey from laboratory discovery to patient bedside.

A Novel Target in a Complex Disease

For decades, the ALS treatment landscape has been frustratingly sparse. Existing therapies like Riluzole and Edaravone offer only modest benefits in slowing progression, leaving a vast unmet need for treatments that can halt or reverse the underlying disease process. Prosetin represents a fundamentally different strategy, aiming to protect the very motor neurons that ALS destroys.

The drug is designed to inhibit a family of enzymes known as MAP4K. Research, much of it pioneered by ProJenX's scientific founders at Columbia University, has identified these enzymes as critical regulators of cellular stress. In ALS, the accumulation of misfolded proteins can trigger a state of chronic stress within motor neurons, leading to their degeneration and death. By blocking MAP4K, prosetin is believed to interrupt this toxic cascade, conferring a broad neuroprotective effect.

Critically, prosetin was engineered to be CNS-penetrant, meaning it can cross the notoriously selective blood-brain barrier. This is a major hurdle in developing drugs for brain diseases, as many promising compounds fail simply because they cannot reach their intended target in the brain and spinal cord. The new data confirms that prosetin achieves target therapeutic concentrations in the body, a prerequisite for it to exert its effects within the central nervous system.

This innovative approach moves beyond managing symptoms or slowing decline by a few months. It aims to intervene directly in a core pathological mechanism, a strategy that independent neurology experts agree is essential for making meaningful progress against ALS.

Clearing Critical Hurdles in Clinical Development

Before a drug can be tested for efficacy, it must first prove its safety. The primary goal of a Phase 1 trial is to answer this fundamental question. According to ProJenX, interim results from the multiple ascending dose portion of the PRO-101 study are encouraging. Across five different dose levels, prosetin was found to be safe and well-tolerated, with no drug-related serious adverse events reported to date, even among participants receiving the treatment long-term.

"Compelling preclinical data supported evaluation of prosetin as a potential disease-modifying treatment for sporadic ALS—but in this first-ever clinical study of a brain-penetrant MAP4K inhibitor, our goal was to answer critical questions about whether prosetin could be safely administered at active dose levels in people living with ALS," said Jinsy Andrews, MD, MSc, Director of the NYU Langone ALS Center and a lead investigator in the study. "Today's data answers that question, supporting continued evaluation of prosetin for ALS."

Beyond safety, the study also confirmed that the drug was hitting its mark. Researchers measured levels of a biomarker called phosphorylated MAP2K4 (pMAP2K4) in participants' blood cells. The data showed a statistically significant, dose-related decrease in this biomarker, providing the first human evidence that prosetin is successfully engaging and inhibiting its MAP4K target. For a company navigating the high-risk, high-reward world of biotech, this target engagement data is a vital de-risking event, providing confidence that the drug’s mechanism of action is viable in patients.

A Partnership Forged by Urgency

The story of prosetin is a powerful example of innovation at the intersection of patient advocacy, academic research, and industry. ProJenX was not born in a traditional venture capital boardroom but grew out of a long-term research collaboration between the non-profit Project ALS and scientists at Columbia University. Project ALS was founded in 1998 by Jenifer Estess and her family and friends after she was diagnosed with the disease, with a mission to accelerate the pace of research through collaboration.

ProJenX was created specifically to commercialize prosetin, the most promising candidate to emerge from this decades-long partnership. This unique origin story underscores a modern paradigm for tackling rare diseases, where patient groups play an integral role in driving and funding the science that may one day lead to a cure. The company's subsequent success in securing $15 million in Series A financing and additional grants from The ALS Association demonstrates a growing confidence within the investment and patient communities in its targeted, science-driven approach.

The Path Forward: From Data to Decisions

While the Phase 1b results are a significant victory, the road ahead is long. The primary portion of the study is complete, but ProJenX continues to gather crucial information through a two-year open-label extension (OLE) available to all participants. This extension will provide invaluable long-term safety data and allow researchers to look for early signals of clinical impact.

During the OLE, investigators will monitor exploratory endpoints, including levels of neurofilament light chain (NfL), a biomarker of nerve damage, and changes in the revised ALS Functional Rating Scale (ALSFRS-R), a standard measure of physical function in people with ALS. This longitudinal data will be instrumental in shaping the future of the prosetin program.

"While PRO-101 was designed primarily to evaluate whether a safe and active dose of prosetin could be achieved in people living with ALS, longitudinal data from the OLE will guide critical decisions around upcoming study design," said Erin Fleming, Co-Founder and Chief Operating Officer of ProJenX. This will allow the company to "select scientifically-driven eligibility criteria and study endpoints for a rigorous Phase 2 study of prosetin in ALS."

The scientific community will get a closer look at the results later this month, when the interim data is presented at the prestigious European Network to Cure ALS (ENCALS) meeting in Madrid. For the thousands of families affected by ALS, these early, carefully validated steps represent a tangible advance and a reason to look toward the future with renewed hope.